We intend to explore two major mechanisms that may underlie less than optimal responses to BcR inhibition by ibrutinib, namely: “bypass” activation from non-BcR immune pathways, in particular the TLRs, resistance to signaling inhibitor-induced apoptosis in a context of BcR anergy associated with decreased dependence on proximal BcR signaling.
